Study to Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection - A Positron Emission Tomography (PET) Study

Recruiting

You are on the General Public view
  • Source

    -
    Public Title Study to Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection - A Positron Emission Tomography (PET) Study
    Acronym Sorry, not currently available
    Source of Record URL http://clinicaltrials.gov/show/NCT00959166
  • Trial

    -
    Health Condition(s) or Problem Acute Hepatitis C; HIV; HIV Infections
    Lay Summary Subtle changes to the brain, which doctors find difficult to detect through conversation or examination, may occur in patients with HIV and/or hepatitis C infection. It is not currently known whether the brain is affected in early (or acute) hepatitis C. This study plans to evaluate what happens to the brain in patients with HIV and early hepatitis C. The investigators will be comparing 3 groups of individuals: - Group 1: Individuals with HIV infection and acute (early) hepatitis C infection - Group 2: Individuals with HIV infection - Group 3: Healthy volunteers Individuals wishing to take part will complete a series of tests assessing different aspects of their brain including: - 2 brain scans using different technology: - Magnetic resonance imaging (MRI) brain scan with spectroscopy - CT PET brain scan - A computer game test which measures brain function - 2 short questionnaires Results of these tests will be analyzed and compared between 3 groups. (from ClinicalTrials.gov)
    Who can enter the trial Inclusion Criteria: 1. HIV-1 antibody positive for at least 12 months 2. Acute HCV (Blood HCV PCR positive with negative PCR within past 8 months) 3. HCV genotype 1 4. Ability to give informed consent 5. Aged > 25 years 6. Male 7. Abbreviated Mental Test Score of at least 8/10 Exclusion Criteria: 1. Evidence of established cirrhosis or encephalopathy 2. Commencing or any change to HIV medications within 12 weeks 3. Active opportunistic infection 4. Taking anti-depressants or any psychoactive medications within past 4 weeks 5. Use of benzodiazepines within past 4 weeks 6. Recent significant head injury 7. Established dementia 8. Alcohol dependence or recreational drug misuse 9. Untreated early syphilis 10. Hepatitis B infection (HBsAg positive) 11. Pregnancy 12. Unable to give informed consent 13. Any contraindication to MR scanning
    Who cannot enter the trial Inclusion Criteria: 1. HIV-1 antibody positive for at least 12 months 2. Acute HCV (Blood HCV PCR positive with negative PCR within past 8 months) 3. HCV genotype 1 4. Ability to give informed consent 5. Aged > 25 years 6. Male 7. Abbreviated Mental Test Score of at least 8/10 Exclusion Criteria: 1. Evidence of established cirrhosis or encephalopathy 2. Commencing or any change to HIV medications within 12 weeks 3. Active opportunistic infection 4. Taking anti-depressants or any psychoactive medications within past 4 weeks 5. Use of benzodiazepines within past 4 weeks 6. Recent significant head injury 7. Established dementia 8. Alcohol dependence or recreational drug misuse 9. Untreated early syphilis 10. Hepatitis B infection (HBsAg positive) 11. Pregnancy 12. Unable to give informed consent 13. Any contraindication to MR scanning
    What will happen Sorry, not currently available
    Primary aim Association of 11C-labelled PK11195 uptake using PET with acute HCV and HIV infection
    Secondary Aim Association of CNS metabolite ratios and neurocognitive performance with acute HCV and HIV infection. Association between patient characteristics and 11C-labelled PK11195 uptake using PET, CNS metabolite ratios and neurocognitive performance.; 2 years; No
    Participant Information Sheet Sorry, not currently available
    Website Sorry, not currently available
    Recruitment Status Recruiting
    Nation England
    Location London
  • Contact

    -
    Contact for Public Queries Alan Winston Principal Investigator Imperial College London
    Contact for Scientific Queries Alan Winston; Principal Investigator; Lucy J Garvey; Sub-Investigator
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.